PATENTLY NON-OBVIOUS II: EXPERIMENTAL STUDY ON THE HINDSIGHT ISSUE BEFORE THE SUPREME COURT IN KSR v. TELEFLEX
نویسنده
چکیده
For the first time in thirty years, the Supreme Court will consider the core patent requirement that an invention be non-obvious. At the heart of the case lies the challenge of how to insulate non-obvious decisions from the distortion of the hindsight bias. This Article reports the latest empirical studies in a line of hindsight research, which present experimental data bearing directly on the issue before the Court: how individuals make non-obvious decisions under existing Supreme Court and Federal Circuit precedent. The study results indicate that the Federal Circuit's suggestion, teaching, or motivation requirement, the precedent challenged before the Supreme Court in KSR v. Teleflex, does not produce erroneous nonobvious outcomes. This result contradicts the claims of the petitioners in KSR and other critics of the suggestion requirement. On the other hand, the results do not demonstrate that the suggestion test ameliorates the hindsight bias in the manner usually claimed by its supporters. An additional study indicates that the Supreme Court's Graham framework does not resolve the hindsight problem either. Given the substantial and confirmed prejudicial effect of the hindsight bias, the Article concludes that the suggestion test should be retained for several reasons: it does not appear to cause the harms hypothesized by its critics, it potentially reduces the hindsight bias for complex technology inventions, and the problem the test confronts (erroneous decisions that an invention is obvious in hindsight) is known and significant while the problem the test is alleged to create (over-compensation for the hindsight bias) is unconfirmed and conjectural. The Article concludes with a recommendation for bifurcating the nonobvious decision at the Patent and Trademark Office. Combined with an earlier proposal for jury trials, these recommendations present the only known means for eliminating the hindsight effect and producing patent decisions that comport with the Patent Act and Supreme Court precedent. * © 2006 Gregory N. Mandel. Associate Dean for Research & Scholarship and Professor of Law, Albany Law School. I am grateful to the participants of the Intellectual Property Scholars Conference at Boalt Hall-Berkeley Law School, the Conference on Empirical Legal Studies at the University of Texas School of Law, Patent Law: Recent Development and Proposals for Reform at Santa Clara School of Law, and the Intellectual Property Colloquium at the University of Arizona College of Law for their helpful comments. 1 MANDEL: PATENTLY NON-OBVIOUS II Published by Yale Law School Legal Scholarship Repository, 2007 YALE JOURNAL OF LAW & TECHNOLOGY 2006-2007
منابع مشابه
"Obvious to try": a proper patentability standard in the pharmaceutical arts?
Pharmaceutical research often entails making small modifications to candidate drug molecules—modifications that might be deemed “obvious to try”—and then studying the largely unpredictable, yet critical, resulting biological effects. Recognizing this characteristic unpredictability, the U.S. Court of Appeals for the Federal Circuit has traditionally upheld the patentability of obvious-to-try ph...
متن کاملKSR v. Teleflex. Part 2: Impact of U.S Supreme Court Patent Law on Canadian and global systems-based innovation ecologies.
متن کامل
Not All Patents Are Created Equal: Bias against Predictable Arts Patents in the Post-ksr Landscape
Investment in intellectual property is considered a shrewd business strategy. However, companies that invest heavily in patenting the results of research and development may later be surprised by their inability to generate revenue from their patent portfolios. This is because those seeking to enforce patents in the predictable arts may find themselves stymied by recent developments in patent j...
متن کاملA New Formula for Analyzing Formulation-patent Obviousness
The generic drug industry, which is estimated to save American consumers $10 billion a year,1 owes much of its current market success to Congress’s enactment of the Hatch-Waxman Act in 1984.2 The Hatch-Waxman Act sought to achieve a delicate balance, one where Americans could obtain unprecedented access to low-cost prescription medicine without somehow undermining the incentive of brand name dr...
متن کاملKSR Int’l Co. v. Teleflex, Inc.: No Obvious Changes for the Biotechnology Market
With the advent of molecular biology, genomics, and proteomics, the intersection between science and law has become increasingly significant. In addition to the ethical and legal concerns surrounding the collection, storage, and use of genomic data, patent disputes for new biotechnologies are quickly becoming part of mainstream business discussions. Under current patent law, new technologies ca...
متن کامل